KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EBITDA (2016 - 2025)

Idexx Laboratories has reported EBITDA over the past 17 years, most recently at $315.6 million for Q4 2025.

  • Quarterly results put EBITDA at $315.6 million for Q4 2025, up 20.6% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (up 20.53% YoY), and the annual figure for FY2025 was $1.4 billion, up 20.53%.
  • EBITDA for Q4 2025 was $315.6 million at Idexx Laboratories, down from $354.8 million in the prior quarter.
  • Over the last five years, EBITDA for IDXX hit a ceiling of $373.0 million in Q2 2025 and a floor of $179.1 million in Q2 2022.
  • Median EBITDA over the past 5 years was $262.7 million (2024), compared with a mean of $270.8 million.
  • Biggest five-year swings in EBITDA: surged 71.57% in 2021 and later plummeted 30.93% in 2022.
  • Idexx Laboratories' EBITDA stood at $199.2 million in 2021, then rose by 13.72% to $226.5 million in 2022, then increased by 8.29% to $245.3 million in 2023, then increased by 6.68% to $261.7 million in 2024, then grew by 20.6% to $315.6 million in 2025.
  • The last three reported values for EBITDA were $315.6 million (Q4 2025), $354.8 million (Q3 2025), and $373.0 million (Q2 2025) per Business Quant data.